Acorn Capital Advisors »

Vyne Therapeutics shares owned by Acorn Capital Advisors

Quarter-by-quarter ownership of Vyne Therapeutics (VYNE) shares owned by Acorn Capital Advisors from 13F filings

Historical chart of Acorn Capital Advisors investment in Vyne Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Vyne Therapeutics held by Acorn Capital Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Vyne Therapeutics by Acorn Capital Advisors

Quarter filed Position value Share count Share price at filing
2025-03-31 $1.2M 786k 1.58
2024-12-31 $1.5M 457k 3.35

More positions owned by Acorn Capital Advisors

Cg Oncology (CGON)
Urogen Pharma (URGN)
Y Mabs Therapeutics (YMAB)
Trevi Therapeutics (TRVI)
Candel Therapeutics (CADL)
Puma Biotechnology (PBYI)
Bicara Therapeutics (BCAX)
Protara Therapeutics Com Stk (TARA)
Terns Pharmaceuticals (TERN)
Onkure Therapeutics Class A Com (OKUR)
Verastem (VSTM)
Cybin Com New (CYBN)
Cardiff Oncology (CRDF)
Optinose Com New
Aadi Bioscience (WHWK)

View all positions for Acorn Capital Advisors

Top funds holding Vyne Therapeutics

Eventide Asset Management
Citadel Advisors
Acorn Capital Advisors
DAFNA Capital Management
Vanguard Group
Exome Asset Management
Palo Alto Investors
Adage Capital Partners GP
Patient Square Capital
Springbok Capital Management
Geode Capital Management
Renaissance Technologies
Schonfeld Strategic Advisors
BlackRock
ADAR1 Capital Management

View all funds holding Vyne Therapeutics